Yazbak believes that all postpartum vaccination should cease immediately and that mothers who ... hair analysis to screen for toxic metals; digestive stool analysis; food allergy ...
Classen began collecting information from international diabetes registries and studying the effects of vaccines on insulin-dependent diabetes over nine years ago. These data revealed a pattern of increased cases of insulin-dependent diabetes in children, correlating with increases in the use of certain vaccines, such as Hemophilus influenza and hepatitis B. In animal model studies, Classen was able to mimic the data from the diabetes registries by inducing diabetes in mice. His studies have predicted rises and falls in the cases of diabetes in many countries according to changes in their vaccination schedules.
Classen cited a large clinical trial of the new Hemophilus influenza vaccine on 114,000 children in Finland. The vaccine was aimed to prevent seven deaths and seven to 26 cases of brain damage per 100,000 children vaccinated. After the first round of vaccinations, Finland saw an extra 58 cases of diabetes per 100,000 children. When a stronger version of the vaccine was administered, an extra 75 cases of diabetes per 100,000 children vaccinated developed. Each time, the increases occurred in statistically significant clusters three to four years after the vaccine was administered.
According to Classen's data, 79 percent of insulin-dependent diabetes in children under the age of ten is due to vaccines. Insulin-dependent diabetes in American children has tripled in the last quarter century, and the average age of diagnosis has dropped from 12 to five years old. Compulsory, government-mandated vaccines have increased from ten to 36 during that same time period. For more information on Classen's work, see the Vaccine Safety Website at www.vaccines.net or contact him at Classen Immunotherapies, 6517 Montrose Avenue, Baltimore, MD 21212; 410-377-4549; Fax: 410-377-8526; or Classen@vaccines.net.
www.hpakids.org/holistic-health/articles/187/1/Vaccine-Conference-Exclusive-